Erlanger Medical Center — Chattanooga, Tennessee

Public research footprint of Erlanger Medical Center, compiled from the ClinicalTrials.gov public registry.

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Atrial Fibrillation · Recurrent Melanoma · Stage IV Cutaneous Melanoma AJCC v6 and v7 · Stage IIA Breast Cancer AJCC v6 and v7

Recently updated registry entries

NCT01547741 — Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating… (Completed)
NCT06952504 — A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab… (Recruiting)
NCT02224781 — Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Erlanger Medical Center?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 07, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.